These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 8053064)

  • 1. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation. A pilot study.
    Hourmant M; Le Mauff B; Le Meur Y; Dantal J; Cantarovich D; Giral M; Caudrelier P; Albericci G; Soulillou JP
    Transplantation; 1994 Aug; 58(3):377-80. PubMed ID: 8053064
    [No Abstract]   [Full Text] [Related]  

  • 2. A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients.
    Le Mauff B; Le Meur Y; Hourmant M; Debray M; Boeffard F; Alberici G; Soulillou JP; Scherrmann JM
    Kidney Int Suppl; 1996 Jan; 53():S44-50. PubMed ID: 8770990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation.
    Hourmant M; Bedrossian J; Durand D; Kessler M; Le Branchu Y; Caudrelier P; Simi B; Soulillou JP
    Transplant Proc; 1995 Feb; 27(1):864. PubMed ID: 7879209
    [No Abstract]   [Full Text] [Related]  

  • 4. CD4 and CD25 monoclonal antibody cocktail in kidney transplant rejection prophylaxis: clinical results of a pilot study.
    Mousson C; Tanter Y; Racadot E; Wijdenes J; Chalopin JM; Chevet D; Hervé P; Rifle G
    Transplant Proc; 1995 Apr; 27(2):1727-8. PubMed ID: 7725472
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of an anti-LFA-1 antibody in renal allograft rejection in sheep.
    Grooby WL; Carter JK; Rao MM; Dewan P; Seymour AE; Brandon M; Russ GR
    Transplant Proc; 1992 Oct; 24(5):2304. PubMed ID: 1413070
    [No Abstract]   [Full Text] [Related]  

  • 6. Phenotypic and functional analysis of graft-infiltrating cells following therapy with anti-interleukin-2 receptor monoclonal antibody and cyclosporine A in the rat.
    Sido B; Morris PJ; Dallman M
    Transplant Proc; 1992 Dec; 24(6):2549-50. PubMed ID: 1465862
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclosporine dosage can be reduced when used in combination with an anti-intercellular adhesion molecule-1 monoclonal antibody in rats undergoing heterotopic heart transplantation.
    Harrison PC; Mainolfi E; Madwed JB
    J Heart Lung Transplant; 1998 Feb; 17(2):150-7. PubMed ID: 9513853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
    van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
    Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation.
    Le Mauff B; Hourmant M; Rougier JP; Hirn M; Dantal J; Baatard R; Cantarovich D; Jacques Y; Soulillou JP
    Transplantation; 1991 Aug; 52(2):291-6. PubMed ID: 1871802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
    Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up.
    Genberg H; Kumlien G; Wennberg L; Berg U; Tydén G
    Transplantation; 2008 Jun; 85(12):1745-54. PubMed ID: 18580466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.
    Vincenti F; Mendez R; Pescovitz M; Rajagopalan PR; Wilkinson AH; Butt K; Laskow D; Slakey DP; Lorber MI; Garg JP; Garovoy M
    Am J Transplant; 2007 Jul; 7(7):1770-7. PubMed ID: 17564637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
    Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
    Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-LFA-1 antibody postpones T-cell receptor triggering while preserving generation of regulatory T cells in T-cell receptor anti-HY transgenic mice.
    Go S; Fleischmann A; Lantz O; Cretolle C; Brousse N; Cerf-Bensussan N; Sarnacki S
    Transplantation; 2006 Jul; 82(1):119-26. PubMed ID: 16861951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
    Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
    J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
    Papp K; Bissonnette R; Krueger JG; Carey W; Gratton D; Gulliver WP; Lui H; Lynde CW; Magee A; Minier D; Ouellet JP; Patel P; Shapiro J; Shear NH; Kramer S; Walicke P; Bauer R; Dedrick RL; Kim SS; White M; Garovoy MR
    J Am Acad Dermatol; 2001 Nov; 45(5):665-74. PubMed ID: 11606914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-lymphocyte-depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts.
    Nakakura EK; McCabe SM; Zheng B; Shorthouse RA; Scheiner TM; Blank G; Jardieu PM; Morris RE
    Transplant Proc; 1993 Feb; 25(1 Pt 1):809-12. PubMed ID: 8438493
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients.
    Stock PG; Lantz M; Light S; Vincenti F
    Transplant Proc; 1996 Apr; 28(2):915-6. PubMed ID: 8623460
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of unresponsiveness to islet allograft by anti-LFA-1 monoclonal antibody treatment.
    Gotoh M; Fukuzaki T; Dono K; Wada H; Kanai T; Monden M; Yagita H; Okumura K; Mori T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):973-4. PubMed ID: 8442286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.